The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I asked this question yesterday but had no replies I'll
try again.
Delayed Publication
Would someone please explain to me what a delayed publication is. Are they buys or sells. There many of these delayed trades after the bell.
Thank you in advance for any replies. Jack
@punpky I totally agree with you as regards all these predictions they are total bull dung. I'm a holder here and topped up this morning @1.75 and now at a profit. This could quite possibly go in reverse on the opening bell tomorrow. The share price will be what it will. We all want it to continue upwards to max our profits, but the reverse could happen.
Also a LTH of HEMO
MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company) a European based pharmaceutical
company specialising in the production and development of innovative medicines for unmet medical
needs, is pleased to announce that following shareholder approval for a new share placement secured
at the Company’s General Meeting on 25th October 2023 (Placement), the Company confirms that it
has received binding commitments from sophisticated and professional investors (Investors) to
subscribe for US$8 million of new shares under the Placement, at an issue price of US$0.255 (A$0.40)
1
per share (on a post-Consolidation basis).
The issue of shares under the Placement is anticipated to occur in the next week, post completion of
the 1:1000 consolidation of capital, as approved by shareholders at the same General Meeting on 25th
October (Consolidation). Participants in the Placement will also receive one free attaching option for
every two shares subscribed for and issued. The options will be exercisable at US$0.32 (A$0.50) (on a
post-Consolidation basis), with a five-year term and will otherwise be issued on the terms and
conditions set out in Schedule 1 of the Notice of Meeting dated 26 September 2023 (Options).
Following the Placement, 31,000,000 fully paid ordinary shares and 15,500,000 Options will be issued
with shareholder approval under Listing Rule 7.1 (obtained 25 October 2023)
MGC Pharmaceuticals Ltd (ASX: MXC) – Trading Halt
Description
The securities of MGC Pharmaceuticals Ltd (‘MXC’) will be placed in trading halt at the request of MXC, pending
it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the
earlier of the commencement of normal trading on Wednesday, 1 November 2023 or when the announcement
is released to the market.
Shares in MXC trading halt, as from today prior to a company announcement on Wednesday
Windows
Where have all the rampers gone?
Long time passing.
Where have all the rampers gone?
Long time ago.
Where have all the shares gone?
The shorters have sold them every one.
Oh, When will you ever learn?
Oh, When will you ever learn?
Rob you won't find anything positive on here re CBX. There's nothing to be positive about.
The management have lined there pockets at our expense.
Yes the cannabinoid industry has a market CBX left shore to late. Even the companies listed and established had there day. These are all trading below there highs. To much competition out there.